HeXun Biosciences Co., Ltd. (TPEX:6986)
Taiwan · Delayed Price · Currency is TWD 61.00
-0.70 (-1.13%)
Jun 3, 2026, 1:26 PM CST
HeXun Biosciences Revenue
In the year 2025, HeXun Biosciences had annual revenue of 293.23M TWD with 2.38% growth. HeXun Biosciences had revenue of 85.26M in the quarter ending December 31, 2025, with 2.90% growth.
Revenue
293.23M
Revenue Growth
+2.38%
P/S Ratio
9.57
Revenue / Employee
5.53M
Employees
53
Market Cap
2.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 293.23M | 6.81M | 2.38% |
| Dec 31, 2024 | 286.42M | 155.85M | 119.36% |
| Dec 31, 2023 | 130.57M | 81.10M | 163.95% |
| Dec 31, 2022 | 49.47M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Syngen Biotech | 2.07B |
| Apex Biotechnology | 1.91B |
| SYN-TECH Chem. & Pharm. | 1.26B |
| Chunghwa Chemical Synthesis & Biotech | 973.15M |
| Genovate Biotechnology | 471.48M |
| BioGend Therapeutics | 229.81M |
| Intech Biopharm | 117.49M |
| GlycoNex Incorporation | 36.35M |